NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

Pramlintide

Prescription ·Strong evidence ·Reviewed May 2026

Pramlintide is an FDA-approved synthetic amylin analog peptide available as prescription Symlin/SymlinPen for adjunctive use in selected people with type 1 or type 2 diabetes who use mealtime insulin. This app supports FDA-approved prescription SymlinPen products only; compounded, research-use, oral/nasal/topical, lyophilized peptide-vial, weight-loss-only, or non-prescribed amylin-analog products are unsupported.

Evidence tier
Strong
Indexed sources
2 2026
Interactions
7
Category
Prescription
Read the sources → Compare profiles
What it's good for
  • Adjunctive post-meal glucose control in selected insulin-treated diabetes patients2
  • Reduces postprandial glucose excursions when used with clinician-directed insulin adjustment
  • May reduce appetite or caloric intake through amylin-mediated satiety effects
  • FDA-approved pen-injector formulation with type-specific titration instructions2
What to watch for
  • Nausea
  • Vomiting
  • Anorexia
  • Prior serious hypersensitivity reaction to pramlintide or product ingredients1
  • Hypoglycemia unawareness1

The bottom line

Evidence rating strong. Most-documented uses: adjunctive post-meal glucose control in selected insulin-treated diabetes patients, reduces postprandial glucose excursions when used with clinician-directed insulin adjustment, may reduce appetite or caloric intake through amylin-mediated satiety effects. 2 sources indexed (2026), with 7 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Pramlintide is an amylin analog that slows gastric emptying, suppresses inappropriate post-meal glucagon secretion, and promotes satiety. Because it is used with insulin, initiation changes post-meal glucose patterns and severe hypoglycemia risk.1,2

Class
Amylin Analog
Dosing

Dosing & protocol.

Common range
Prescriber-directed dosing only. Symlin initiation, titration, and mealtime-insulin adjustment must follow the FDA-approved label and individualized diabetes plan; NutriStack does not provide self-directed pramlintide initiation or dose escalation.
Recommended form
FDA-approved prescription SymlinPen pramlintide acetate injection selected by the diabetes clinician. Do not substitute compounded pramlintide, cagrilintide/CagriSema-type products, research amylin analogs, unlabeled vials, or non-prescribed products.

Subcutaneous injection before major meals as prescribed. Labeling directs abdomen or thigh injection, not arm injection, and requires pramlintide and insulin to be given as separate injections at distinct sites.2

Safety

Full safety detail.

Side effects

  • Nausea
  • Vomiting
  • Anorexia
  • Headache
  • Severe hypoglycemia when used with insulin
  • Injection-site reactions

Contraindications

  • Prior serious hypersensitivity reaction to pramlintide or product ingredients1
  • Hypoglycemia unawareness1
  • Confirmed gastroparesis1
Interactions

Interaction records.

SeriousCaution

Berberine

Berberine can lower glucose through AMPK-linked metabolic effects and may improve insulin sensitivity. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Berberine can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Berberine while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

SeriousCaution

Berberine HCl

Berberine HCl can lower glucose through AMPK-linked metabolic effects and may improve insulin sensitivity. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Berberine HCl can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Berberine HCl while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

SeriousCaution

Alpha-Lipoic Acid

Alpha-lipoic acid may improve insulin-mediated glucose disposal and has rare reports of insulin autoimmune syndrome with severe hypoglycemia. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Alpha-Lipoic Acid can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Alpha-Lipoic Acid while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

SeriousCaution

Chromium

Chromium may modestly improve insulin sensitivity in some people with diabetes or insulin resistance. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Chromium can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Chromium while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

SeriousCaution

Fenugreek

Fenugreek seed fiber and constituents may lower fasting or post-meal glucose in diabetes studies. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Fenugreek can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Fenugreek while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

SeriousCaution

Vanadium

Vanadium salts have insulin-mimetic activity and small human studies show glucose-lowering or insulin-sensitizing effects. Pramlintide is used with mealtime insulin and carries a boxed warning for severe hypoglycemia, particularly in type 1 diabetes. Adding or stopping Vanadium can change post-meal glucose patterns and hypoglycemia risk during pramlintide-insulin therapy. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

Recommendation: Do not start, stop, or substantially change Vanadium while using pramlintide with mealtime insulin without diabetes-clinician awareness. Follow the prescribed glucose-monitoring plan, keep fast-acting carbohydrate available, and review recurrent lows promptly, especially within 3 hours after Symlin injection. Pramlintide and insulin adjustments should be clinician-directed. This is a pharmacodynamic glucose-lowering issue; dose spacing does not reliably prevent it.

ModerateCaution

Psyllium Husk

Psyllium forms a viscous gel that can slow carbohydrate absorption and delay or bind some oral products. Pramlintide slows gastric emptying and its label has specific oral-medication timing rules. Together, the main concerns are unpredictable post-meal glucose patterns, gastrointestinal intolerance, and missed timing for critical oral medications.

Recommendation: Use psyllium with pramlintide only with attention to meal size, carbohydrate intake, nausea, constipation, and the diabetes glucose-monitoring plan. Symlin labeling says oral medications where rapid onset or a threshold concentration is critical should be taken at least 1 hour before or 2 hours after Symlin injection; also separate other oral medications from psyllium as their labels or clinicians direct. Do not use dose spacing between psyllium and pramlintide as a substitute for clinician-directed glucose monitoring.

Search all 7 interaction records for Pramlintide →

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Reference material

2
  • 1SYMLINPEN (pramlintide acetate) injection: prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026

    Label includes boxed severe hypoglycemia warning with insulin, contraindications for serious hypersensitivity, hypoglycemia unawareness, and confirmed gastroparesis, separate-injection/no-mixing requirements, SymlinPen sharing warning, oral-medication timing, and PLLR pregnancy language.

  • 2SYMLIN (pramlintide acetate) injection: FDA SPL prescribing informationSource linkedURLU.S. Food and Drug Administration / DailyMed · Official prescribing information and FDA drug safety communication · 2026

    Official SPL view confirms mealtime-insulin dose reduction at initiation, major-meal dosing context, at least 3-day titration intervals, and pen-injector strengths.

Keep exploring

Deep dives & adjacent profiles.

Goal hubMetabolic Health
SemaglutidePrescriptionLiraglutidePrescriptionInsulin LisproPrescriptionInsulin GlarginePrescriptionInsulin AspartPrescriptionDulaglutidePrescription

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Pramlintide in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.